

Global Fast-acting Human Insulin Market Growth 2026-2032

<https://marketpublishers.com/r/GD054396F322EN.html>

Date: September 2026

Pages: 112

Price: US\$ 3,660.00 (Single User License)

ID: GD054396F322EN

Abstracts

The global Fast-acting Human Insulin market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

United States market for Fast-acting Human Insulin is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Fast-acting Human Insulin is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Fast-acting Human Insulin is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Fast-acting Human Insulin players cover Sanofi, Geropharm, Wockhardt, Novo Nordisk, Eli Lilly and Company, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the "Fast-acting Human Insulin Industry Forecast" looks at past sales and reviews total world Fast-acting Human Insulin sales in 2025, providing a comprehensive analysis by region and market sector of projected Fast-acting Human Insulin sales for 2026 through 2032. With Fast-acting Human Insulin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Fast-acting Human Insulin industry.

This Insight Report provides a comprehensive analysis of the global Fast-acting Human

Insulin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Fast-acting Human Insulin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Fast-acting Human Insulin market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Fast-acting Human Insulin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Fast-acting Human Insulin.

This report presents a comprehensive overview, market shares, and growth opportunities of Fast-acting Human Insulin market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Lispro Insulin

Aspart Insulin

Glulisine Insulin

Segmentation by Application:

Type 1 Diabetes

Type 2 Diabetes

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Sanofi

Geropharm

Wockhardt

Novo Nordisk

Eli Lilly and Company

Mannkind

Biocon

Julphar

ADOCIA

Tonghua Dongbao Pharmaceutical

Gan & Lee Pharmaceuticals

Zhejiang Hisun Pharmaceutical

Wuhan Biology Chemical Pharmacy

Key Questions Addressed in this Report

Global Fast-acting Human Insulin Market Growth 2026-2032

What is the 10-year outlook for the global Fast-acting Human Insulin market?

What factors are driving Fast-acting Human Insulin market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Fast-acting Human Insulin market opportunities vary by end market size?

How does Fast-acting Human Insulin break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Fast-acting Human Insulin Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for Fast-acting Human Insulin by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for Fast-acting Human Insulin by Country/Region, 2021, 2025 & 2032
- 2.2 Fast-acting Human Insulin Segment by Type
 - 2.2.1 Lispro Insulin
 - 2.2.2 Aspart Insulin
 - 2.2.3 Glulisine Insulin
 - 2.2.4 Fast-acting Human Insulin Sales by Type
 - 2.2.4.1 Global Fast-acting Human Insulin Sales Market Share by Type (2021-2026)
 - 2.2.4.2 Global Fast-acting Human Insulin Revenue and Market Share by Type (2021-2026)
 - 2.2.4.3 Global Fast-acting Human Insulin Sale Price by Type (2021-2026)
- 2.3 Fast-acting Human Insulin Segment by Application
 - 2.3.1 Type 1 Diabetes
 - 2.3.2 Type 2 Diabetes
 - 2.3.3 Fast-acting Human Insulin Sales by Application
 - 2.3.3.1 Global Fast-acting Human Insulin Sale Market Share by Application (2021-2026)
 - 2.3.3.2 Global Fast-acting Human Insulin Revenue and Market Share by Application (2021-2026)
 - 2.3.3.3 Global Fast-acting Human Insulin Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

- 3.1 Global Fast-acting Human Insulin Breakdown Data by Company
 - 3.1.1 Global Fast-acting Human Insulin Annual Sales by Company (2021-2026)
 - 3.1.2 Global Fast-acting Human Insulin Sales Market Share by Company (2021-2026)
- 3.2 Global Fast-acting Human Insulin Annual Revenue by Company (2021-2026)
 - 3.2.1 Global Fast-acting Human Insulin Revenue by Company (2021-2026)
 - 3.2.2 Global Fast-acting Human Insulin Revenue Market Share by Company (2021-2026)
- 3.3 Global Fast-acting Human Insulin Sale Price by Company
- 3.4 Key Manufacturers Fast-acting Human Insulin Producing Area Distribution, Sales Area, Product Type
 - 3.4.1 Key Manufacturers Fast-acting Human Insulin Product Location Distribution
 - 3.4.2 Players Fast-acting Human Insulin Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
 - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
- 3.6 New Products and Potential Entrants
- 3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR FAST-ACTING HUMAN INSULIN BY GEOGRAPHIC REGION

- 4.1 World Historic Fast-acting Human Insulin Market Size by Geographic Region (2021-2026)
 - 4.1.1 Global Fast-acting Human Insulin Annual Sales by Geographic Region (2021-2026)
 - 4.1.2 Global Fast-acting Human Insulin Annual Revenue by Geographic Region (2021-2026)
- 4.2 World Historic Fast-acting Human Insulin Market Size by Country/Region (2021-2026)
 - 4.2.1 Global Fast-acting Human Insulin Annual Sales by Country/Region (2021-2026)
 - 4.2.2 Global Fast-acting Human Insulin Annual Revenue by Country/Region (2021-2026)
- 4.3 Americas Fast-acting Human Insulin Sales Growth
- 4.4 APAC Fast-acting Human Insulin Sales Growth
- 4.5 Europe Fast-acting Human Insulin Sales Growth
- 4.6 Middle East & Africa Fast-acting Human Insulin Sales Growth

5 AMERICAS

5.1 Americas Fast-acting Human Insulin Sales by Country

5.1.1 Americas Fast-acting Human Insulin Sales by Country (2021-2026)

5.1.2 Americas Fast-acting Human Insulin Revenue by Country (2021-2026)

5.2 Americas Fast-acting Human Insulin Sales by Type (2021-2026)

5.3 Americas Fast-acting Human Insulin Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Fast-acting Human Insulin Sales by Region

6.1.1 APAC Fast-acting Human Insulin Sales by Region (2021-2026)

6.1.2 APAC Fast-acting Human Insulin Revenue by Region (2021-2026)

6.2 APAC Fast-acting Human Insulin Sales by Type (2021-2026)

6.3 APAC Fast-acting Human Insulin Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Fast-acting Human Insulin by Country

7.1.1 Europe Fast-acting Human Insulin Sales by Country (2021-2026)

7.1.2 Europe Fast-acting Human Insulin Revenue by Country (2021-2026)

7.2 Europe Fast-acting Human Insulin Sales by Type (2021-2026)

7.3 Europe Fast-acting Human Insulin Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Fast-acting Human Insulin by Country

8.1.1 Middle East & Africa Fast-acting Human Insulin Sales by Country (2021-2026)

8.1.2 Middle East & Africa Fast-acting Human Insulin Revenue by Country (2021-2026)

8.2 Middle East & Africa Fast-acting Human Insulin Sales by Type (2021-2026)

8.3 Middle East & Africa Fast-acting Human Insulin Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Fast-acting Human Insulin

10.3 Manufacturing Process Analysis of Fast-acting Human Insulin

10.4 Industry Chain Structure of Fast-acting Human Insulin

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Fast-acting Human Insulin Distributors

11.3 Fast-acting Human Insulin Customer

12 WORLD FORECAST REVIEW FOR FAST-ACTING HUMAN INSULIN BY GEOGRAPHIC REGION

- 12.1 Global Fast-acting Human Insulin Market Size Forecast by Region
 - 12.1.1 Global Fast-acting Human Insulin Forecast by Region (2027-2032)
 - 12.1.2 Global Fast-acting Human Insulin Annual Revenue Forecast by Region (2027-2032)
- 12.2 Americas Forecast by Country (2027-2032)
- 12.3 APAC Forecast by Region (2027-2032)
- 12.4 Europe Forecast by Country (2027-2032)
- 12.5 Middle East & Africa Forecast by Country (2027-2032)
- 12.6 Global Fast-acting Human Insulin Forecast by Type (2027-2032)
- 12.7 Global Fast-acting Human Insulin Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

- 13.1 Sanofi
 - 13.1.1 Sanofi Company Information
 - 13.1.2 Sanofi Fast-acting Human Insulin Product Portfolios and Specifications
 - 13.1.3 Sanofi Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.1.4 Sanofi Main Business Overview
 - 13.1.5 Sanofi Latest Developments
- 13.2 Geropharm
 - 13.2.1 Geropharm Company Information
 - 13.2.2 Geropharm Fast-acting Human Insulin Product Portfolios and Specifications
 - 13.2.3 Geropharm Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.2.4 Geropharm Main Business Overview
 - 13.2.5 Geropharm Latest Developments
- 13.3 Wockhardt
 - 13.3.1 Wockhardt Company Information
 - 13.3.2 Wockhardt Fast-acting Human Insulin Product Portfolios and Specifications
 - 13.3.3 Wockhardt Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.3.4 Wockhardt Main Business Overview
 - 13.3.5 Wockhardt Latest Developments
- 13.4 Novo Nordisk
 - 13.4.1 Novo Nordisk Company Information
 - 13.4.2 Novo Nordisk Fast-acting Human Insulin Product Portfolios and Specifications
 - 13.4.3 Novo Nordisk Fast-acting Human Insulin Sales, Revenue, Price and Gross

Margin (2021-2026)

13.4.4 Novo Nordisk Main Business Overview

13.4.5 Novo Nordisk Latest Developments

13.5 Eli Lilly and Company

13.5.1 Eli Lilly and Company Company Information

13.5.2 Eli Lilly and Company Fast-acting Human Insulin Product Portfolios and Specifications

13.5.3 Eli Lilly and Company Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 Eli Lilly and Company Main Business Overview

13.5.5 Eli Lilly and Company Latest Developments

13.6 Mannkind

13.6.1 Mannkind Company Information

13.6.2 Mannkind Fast-acting Human Insulin Product Portfolios and Specifications

13.6.3 Mannkind Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2021-2026)

13.6.4 Mannkind Main Business Overview

13.6.5 Mannkind Latest Developments

13.7 Biocon

13.7.1 Biocon Company Information

13.7.2 Biocon Fast-acting Human Insulin Product Portfolios and Specifications

13.7.3 Biocon Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 Biocon Main Business Overview

13.7.5 Biocon Latest Developments

13.8 Julphar

13.8.1 Julphar Company Information

13.8.2 Julphar Fast-acting Human Insulin Product Portfolios and Specifications

13.8.3 Julphar Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Julphar Main Business Overview

13.8.5 Julphar Latest Developments

13.9 ADOCIA

13.9.1 ADOCIA Company Information

13.9.2 ADOCIA Fast-acting Human Insulin Product Portfolios and Specifications

13.9.3 ADOCIA Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2021-2026)

13.9.4 ADOCIA Main Business Overview

13.9.5 ADOCIA Latest Developments

13.10 Tonghua Dongbao Pharmaceutical

13.10.1 Tonghua Dongbao Pharmaceutical Company Information

13.10.2 Tonghua Dongbao Pharmaceutical Fast-acting Human Insulin Product Portfolios and Specifications

13.10.3 Tonghua Dongbao Pharmaceutical Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2021-2026)

13.10.4 Tonghua Dongbao Pharmaceutical Main Business Overview

13.10.5 Tonghua Dongbao Pharmaceutical Latest Developments

13.11 Gan & Lee Pharmaceuticals

13.11.1 Gan & Lee Pharmaceuticals Company Information

13.11.2 Gan & Lee Pharmaceuticals Fast-acting Human Insulin Product Portfolios and Specifications

13.11.3 Gan & Lee Pharmaceuticals Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2021-2026)

13.11.4 Gan & Lee Pharmaceuticals Main Business Overview

13.11.5 Gan & Lee Pharmaceuticals Latest Developments

13.12 Zhejiang Hisun Pharmaceutical

13.12.1 Zhejiang Hisun Pharmaceutical Company Information

13.12.2 Zhejiang Hisun Pharmaceutical Fast-acting Human Insulin Product Portfolios and Specifications

13.12.3 Zhejiang Hisun Pharmaceutical Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2021-2026)

13.12.4 Zhejiang Hisun Pharmaceutical Main Business Overview

13.12.5 Zhejiang Hisun Pharmaceutical Latest Developments

13.13 Wuhan Biology Chemical Pharmacy

13.13.1 Wuhan Biology Chemical Pharmacy Company Information

13.13.2 Wuhan Biology Chemical Pharmacy Fast-acting Human Insulin Product Portfolios and Specifications

13.13.3 Wuhan Biology Chemical Pharmacy Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2021-2026)

13.13.4 Wuhan Biology Chemical Pharmacy Main Business Overview

13.13.5 Wuhan Biology Chemical Pharmacy Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Fast-acting Human Insulin Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Table 2. Fast-acting Human Insulin Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)
- Table 3. Major Players of Lispro Insulin
- Table 4. Major Players of Aspart Insulin
- Table 5. Major Players of Glulisine Insulin
- Table 6. Global Fast-acting Human Insulin Sales by Type (2021-2026) & (K Units)
- Table 7. Global Fast-acting Human Insulin Sales Market Share by Type (2021-2026)
- Table 8. Global Fast-acting Human Insulin Revenue by Type (2021-2026) & (\$ million)
- Table 9. Global Fast-acting Human Insulin Revenue Market Share by Type (2021-2026)
- Table 10. Global Fast-acting Human Insulin Sale Price by Type (2021-2026) & (US\$/Unit)
- Table 11. Global Fast-acting Human Insulin Sale by Application (2021-2026) & (K Units)
- Table 12. Global Fast-acting Human Insulin Sale Market Share by Application (2021-2026)
- Table 13. Global Fast-acting Human Insulin Revenue by Application (2021-2026) & (\$ million)
- Table 14. Global Fast-acting Human Insulin Revenue Market Share by Application (2021-2026)
- Table 15. Global Fast-acting Human Insulin Sale Price by Application (2021-2026) & (US\$/Unit)
- Table 16. Global Fast-acting Human Insulin Sales by Company (2021-2026) & (K Units)
- Table 17. Global Fast-acting Human Insulin Sales Market Share by Company (2021-2026)
- Table 18. Global Fast-acting Human Insulin Revenue by Company (2021-2026) & (\$ millions)
- Table 19. Global Fast-acting Human Insulin Revenue Market Share by Company (2021-2026)
- Table 20. Global Fast-acting Human Insulin Sale Price by Company (2021-2026) & (US\$/Unit)
- Table 21. Key Manufacturers Fast-acting Human Insulin Producing Area Distribution and Sales Area
- Table 22. Players Fast-acting Human Insulin Products Offered
- Table 23. Fast-acting Human Insulin Concentration Ratio (CR3, CR5 and CR10) &

(2024-2026)

Table 24. New Products and Potential Entrants

Table 25. Market M&A Activity & Strategy

Table 26. Global Fast-acting Human Insulin Sales by Geographic Region (2021-2026) & (K Units)

Table 27. Global Fast-acting Human Insulin Sales Market Share Geographic Region (2021-2026)

Table 28. Global Fast-acting Human Insulin Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 29. Global Fast-acting Human Insulin Revenue Market Share by Geographic Region (2021-2026)

Table 30. Global Fast-acting Human Insulin Sales by Country/Region (2021-2026) & (K Units)

Table 31. Global Fast-acting Human Insulin Sales Market Share by Country/Region (2021-2026)

Table 32. Global Fast-acting Human Insulin Revenue by Country/Region (2021-2026) & (\$ millions)

Table 33. Global Fast-acting Human Insulin Revenue Market Share by Country/Region (2021-2026)

Table 34. Americas Fast-acting Human Insulin Sales by Country (2021-2026) & (K Units)

Table 35. Americas Fast-acting Human Insulin Sales Market Share by Country (2021-2026)

Table 36. Americas Fast-acting Human Insulin Revenue by Country (2021-2026) & (\$ millions)

Table 37. Americas Fast-acting Human Insulin Sales by Type (2021-2026) & (K Units)

Table 38. Americas Fast-acting Human Insulin Sales by Application (2021-2026) & (K Units)

Table 39. APAC Fast-acting Human Insulin Sales by Region (2021-2026) & (K Units)

Table 40. APAC Fast-acting Human Insulin Sales Market Share by Region (2021-2026)

Table 41. APAC Fast-acting Human Insulin Revenue by Region (2021-2026) & (\$ millions)

Table 42. APAC Fast-acting Human Insulin Sales by Type (2021-2026) & (K Units)

Table 43. APAC Fast-acting Human Insulin Sales by Application (2021-2026) & (K Units)

Table 44. Europe Fast-acting Human Insulin Sales by Country (2021-2026) & (K Units)

Table 45. Europe Fast-acting Human Insulin Revenue by Country (2021-2026) & (\$ millions)

Table 46. Europe Fast-acting Human Insulin Sales by Type (2021-2026) & (K Units)

Table 47. Europe Fast-acting Human Insulin Sales by Application (2021-2026) & (K Units)

Table 48. Middle East & Africa Fast-acting Human Insulin Sales by Country (2021-2026) & (K Units)

Table 49. Middle East & Africa Fast-acting Human Insulin Revenue Market Share by Country (2021-2026)

Table 50. Middle East & Africa Fast-acting Human Insulin Sales by Type (2021-2026) & (K Units)

Table 51. Middle East & Africa Fast-acting Human Insulin Sales by Application (2021-2026) & (K Units)

Table 52. Key Market Drivers & Growth Opportunities of Fast-acting Human Insulin

Table 53. Key Market Challenges & Risks of Fast-acting Human Insulin

Table 54. Key Industry Trends of Fast-acting Human Insulin

Table 55. Fast-acting Human Insulin Raw Material

Table 56. Key Suppliers of Raw Materials

Table 57. Fast-acting Human Insulin Distributors List

Table 58. Fast-acting Human Insulin Customer List

Table 59. Global Fast-acting Human Insulin Sales Forecast by Region (2027-2032) & (K Units)

Table 60. Global Fast-acting Human Insulin Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 61. Americas Fast-acting Human Insulin Sales Forecast by Country (2027-2032) & (K Units)

Table 62. Americas Fast-acting Human Insulin Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 63. APAC Fast-acting Human Insulin Sales Forecast by Region (2027-2032) & (K Units)

Table 64. APAC Fast-acting Human Insulin Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 65. Europe Fast-acting Human Insulin Sales Forecast by Country (2027-2032) & (K Units)

Table 66. Europe Fast-acting Human Insulin Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 67. Middle East & Africa Fast-acting Human Insulin Sales Forecast by Country (2027-2032) & (K Units)

Table 68. Middle East & Africa Fast-acting Human Insulin Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 69. Global Fast-acting Human Insulin Sales Forecast by Type (2027-2032) & (K Units)

Table 70. Global Fast-acting Human Insulin Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 71. Global Fast-acting Human Insulin Sales Forecast by Application (2027-2032) & (K Units)

Table 72. Global Fast-acting Human Insulin Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 73. Sanofi Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 74. Sanofi Fast-acting Human Insulin Product Portfolios and Specifications

Table 75. Sanofi Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 76. Sanofi Main Business

Table 77. Sanofi Latest Developments

Table 78. Geropharm Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 79. Geropharm Fast-acting Human Insulin Product Portfolios and Specifications

Table 80. Geropharm Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 81. Geropharm Main Business

Table 82. Geropharm Latest Developments

Table 83. Wockhardt Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 84. Wockhardt Fast-acting Human Insulin Product Portfolios and Specifications

Table 85. Wockhardt Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 86. Wockhardt Main Business

Table 87. Wockhardt Latest Developments

Table 88. Novo Nordisk Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 89. Novo Nordisk Fast-acting Human Insulin Product Portfolios and Specifications

Table 90. Novo Nordisk Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 91. Novo Nordisk Main Business

Table 92. Novo Nordisk Latest Developments

Table 93. Eli Lilly and Company Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 94. Eli Lilly and Company Fast-acting Human Insulin Product Portfolios and Specifications

Table 95. Eli Lilly and Company Fast-acting Human Insulin Sales (K Units), Revenue (\$

Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 96. Eli Lilly and Company Main Business

Table 97. Eli Lilly and Company Latest Developments

Table 98. Mannkind Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 99. Mannkind Fast-acting Human Insulin Product Portfolios and Specifications

Table 100. Mannkind Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 101. Mannkind Main Business

Table 102. Mannkind Latest Developments

Table 103. Biocon Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 104. Biocon Fast-acting Human Insulin Product Portfolios and Specifications

Table 105. Biocon Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 106. Biocon Main Business

Table 107. Biocon Latest Developments

Table 108. Julphar Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 109. Julphar Fast-acting Human Insulin Product Portfolios and Specifications

Table 110. Julphar Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 111. Julphar Main Business

Table 112. Julphar Latest Developments

Table 113. ADOCIA Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 114. ADOCIA Fast-acting Human Insulin Product Portfolios and Specifications

Table 115. ADOCIA Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 116. ADOCIA Main Business

Table 117. ADOCIA Latest Developments

Table 118. Tonghua Dongbao Pharmaceutical Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 119. Tonghua Dongbao Pharmaceutical Fast-acting Human Insulin Product Portfolios and Specifications

Table 120. Tonghua Dongbao Pharmaceutical Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 121. Tonghua Dongbao Pharmaceutical Main Business

Table 122. Tonghua Dongbao Pharmaceutical Latest Developments

Table 123. Gan & Lee Pharmaceuticals Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 124. Gan & Lee Pharmaceuticals Fast-acting Human Insulin Product Portfolios and Specifications

Table 125. Gan & Lee Pharmaceuticals Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 126. Gan & Lee Pharmaceuticals Main Business

Table 127. Gan & Lee Pharmaceuticals Latest Developments

Table 128. Zhejiang Hisun Pharmaceutical Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 129. Zhejiang Hisun Pharmaceutical Fast-acting Human Insulin Product Portfolios and Specifications

Table 130. Zhejiang Hisun Pharmaceutical Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 131. Zhejiang Hisun Pharmaceutical Main Business

Table 132. Zhejiang Hisun Pharmaceutical Latest Developments

Table 133. Wuhan Biology Chemical Pharmacy Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 134. Wuhan Biology Chemical Pharmacy Fast-acting Human Insulin Product Portfolios and Specifications

Table 135. Wuhan Biology Chemical Pharmacy Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 136. Wuhan Biology Chemical Pharmacy Main Business

Table 137. Wuhan Biology Chemical Pharmacy Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Fast-acting Human Insulin
- Figure 2. Fast-acting Human Insulin Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Fast-acting Human Insulin Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Fast-acting Human Insulin Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Fast-acting Human Insulin Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Fast-acting Human Insulin Sales Market Share by Country/Region (2025)
- Figure 10. Fast-acting Human Insulin Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Lispro Insulin
- Figure 12. Product Picture of Aspart Insulin
- Figure 13. Product Picture of Glulisine Insulin
- Figure 14. Global Fast-acting Human Insulin Sales Market Share by Type in 2026
- Figure 15. Global Fast-acting Human Insulin Revenue Market Share by Type (2021-2026)
- Figure 16. Fast-acting Human Insulin Consumed in Type 1 Diabetes
- Figure 17. Global Fast-acting Human Insulin Market: Type 1 Diabetes (2021-2026) & (K Units)
- Figure 18. Fast-acting Human Insulin Consumed in Type 2 Diabetes
- Figure 19. Global Fast-acting Human Insulin Market: Type 2 Diabetes (2021-2026) & (K Units)
- Figure 20. Global Fast-acting Human Insulin Sale Market Share by Application (2025)
- Figure 21. Global Fast-acting Human Insulin Revenue Market Share by Application in 2026
- Figure 22. Fast-acting Human Insulin Sales by Company in 2026 (K Units)
- Figure 23. Global Fast-acting Human Insulin Sales Market Share by Company in 2026
- Figure 24. Fast-acting Human Insulin Revenue by Company in 2026 (\$ millions)
- Figure 25. Global Fast-acting Human Insulin Revenue Market Share by Company in 2026
- Figure 26. Global Fast-acting Human Insulin Sales Market Share by Geographic Region (2021-2026)

Figure 27. Global Fast-acting Human Insulin Revenue Market Share by Geographic Region in 2026

Figure 28. Americas Fast-acting Human Insulin Sales 2021-2026 (K Units)

Figure 29. Americas Fast-acting Human Insulin Revenue 2021-2026 (\$ millions)

Figure 30. APAC Fast-acting Human Insulin Sales 2021-2026 (K Units)

Figure 31. APAC Fast-acting Human Insulin Revenue 2021-2026 (\$ millions)

Figure 32. Europe Fast-acting Human Insulin Sales 2021-2026 (K Units)

Figure 33. Europe Fast-acting Human Insulin Revenue 2021-2026 (\$ millions)

Figure 34. Middle East & Africa Fast-acting Human Insulin Sales 2021-2026 (K Units)

Figure 35. Middle East & Africa Fast-acting Human Insulin Revenue 2021-2026 (\$ millions)

Figure 36. Americas Fast-acting Human Insulin Sales Market Share by Country in 2026

Figure 37. Americas Fast-acting Human Insulin Revenue Market Share by Country (2021-2026)

Figure 38. Americas Fast-acting Human Insulin Sales Market Share by Type (2021-2026)

Figure 39. Americas Fast-acting Human Insulin Sales Market Share by Application (2021-2026)

Figure 40. United States Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 41. Canada Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 42. Mexico Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 43. Brazil Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 44. APAC Fast-acting Human Insulin Sales Market Share by Region in 2026

Figure 45. APAC Fast-acting Human Insulin Revenue Market Share by Region (2021-2026)

Figure 46. APAC Fast-acting Human Insulin Sales Market Share by Type (2021-2026)

Figure 47. APAC Fast-acting Human Insulin Sales Market Share by Application (2021-2026)

Figure 48. China Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 49. Japan Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 50. South Korea Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 51. Southeast Asia Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 52. India Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 53. Australia Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 54. China Taiwan Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 55. Europe Fast-acting Human Insulin Sales Market Share by Country in 2026

Figure 56. Europe Fast-acting Human Insulin Revenue Market Share by Country (2021-2026)

Figure 57. Europe Fast-acting Human Insulin Sales Market Share by Type (2021-2026)

Figure 58. Europe Fast-acting Human Insulin Sales Market Share by Application (2021-2026)

Figure 59. Germany Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 60. France Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 61. UK Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 62. Italy Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 63. Russia Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 64. Middle East & Africa Fast-acting Human Insulin Sales Market Share by Country (2021-2026)

Figure 65. Middle East & Africa Fast-acting Human Insulin Sales Market Share by Type (2021-2026)

Figure 66. Middle East & Africa Fast-acting Human Insulin Sales Market Share by Application (2021-2026)

Figure 67. Egypt Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 68. South Africa Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 69. Israel Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 70. Turkey Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 71. GCC Countries Fast-acting Human Insulin Revenue Growth 2021-2026 (\$ millions)

Figure 72. Manufacturing Cost Structure Analysis of Fast-acting Human Insulin in 2026

Figure 73. Manufacturing Process Analysis of Fast-acting Human Insulin

Figure 74. Industry Chain Structure of Fast-acting Human Insulin

Figure 75. Channels of Distribution

Figure 76. Global Fast-acting Human Insulin Sales Market Forecast by Region (2027-2032)

Figure 77. Global Fast-acting Human Insulin Revenue Market Share Forecast by Region (2027-2032)

Figure 78. Global Fast-acting Human Insulin Sales Market Share Forecast by Type (2027-2032)

Figure 79. Global Fast-acting Human Insulin Revenue Market Share Forecast by Type (2027-2032)

Figure 80. Global Fast-acting Human Insulin Sales Market Share Forecast by Application (2027-2032)

Figure 81. Global Fast-acting Human Insulin Revenue Market Share Forecast by

Application (2027-2032)

I would like to order

Product name: Global Fast-acting Human Insulin Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/GD054396F322EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD054396F322EN.html>